‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta‐analysis’

@article{Satapathy2019PeptideRR,
  title={‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta‐analysis’},
  author={Swayamjeet Satapathy and B. Mittal and A. Bhansali},
  journal={Clinical Endocrinology},
  year={2019},
  volume={91},
  pages={718 - 727}
}
  • Swayamjeet Satapathy, B. Mittal, A. Bhansali
  • Published 2019
  • Medicine
  • Clinical Endocrinology
  • Inoperable and metastatic pheochromocytomas and paragangliomas (PPGLs) present a therapeutic challenge with current treatment options being limited to radiolabelled meta‐iodo‐benzyl‐guanidine (MIBG) and systemic chemotherapy. Peptide receptor radionuclide therapy (PRRT) seems to be a promising option for these patients with few studies reporting favourable response. This systematic review was conducted to evaluate the efficacy and safety of PRRT in patients with advanced PPGLs. 
    8 Citations

    References

    SHOWING 1-10 OF 43 REFERENCES
    Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
    • 56
    • PDF